We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 82.8% of patients treated with Vtama achieved the ...
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis. More research on ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...
The US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, "including intertriginous areas," in patients aged 12 years and older.
The woman had axillary granular parakeratosis (GP), a benign condition. First described in 1991, this disease presents with erythematous hyperpigmented and hyperkeratotic papules and plaques in ...
Vision – To be the world's leading and most trusted provider of information and services that will make a real difference in clinical practice and improve outcomes for patients. Mission – To lead the ...
A 55-year-old woman was referred to the dermatology department for an intertriginous eruption of one week’s duration. She had undergone breast-conserving surgery for stage 2 breast cancer. Two weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback